JavaScript seems to be disabled in your browser. You must have JavaScript enabled in your browser to utilize the functionality of this website.
Description: Talazoparib tosylate (formerly called BMN673 and MDV3800; trade name: Talzenna), the tosylate salt of talazoparib, is an inhibitor of PARP1/2 poly(ADP-ribose) polymerase with potential antineoplastic activity. It inhibits PARP with an IC50 of 0.58 nM in a cell-free assay. It exhibits favorable metabolic stability, oral bioavailability, and pharmacokinetic properties. On Oct 16 2018, Talazoparib was approved by FDA for the treatment of locally advanced or metastatic breast cancer patients with a germline BRCA mutation.
References: Clin Cancer Res. 2013 Sep 15; 19(18):5003-15; Clin Cancer Res. 2014 Apr 15; 20(8):2237.
Related CAS#:1207456-01-6 (free base); 1207456-00-5; 1207454-56-5 (racemic mixture)
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.
Request Data Sheet
Request product datasheet
Request safety datasheet
Compare
Add to wishlist
Recommend by mail
Get an offer
Request delivery time
Ask a technical question
Submit a bulk request
sales@hoelzel.de
« Back
Subscribe, get 15% off every fifth order and have your items delivered on time!
Forgot Your Password?
Not yet registered? Create account here!